News

Tasimelteon is a circadian regulator in development for the treatment of Non-24-Hour Disorder in totally blind individuals with no light perception. This observation was made in four patients

CPX-351 is the Celator’s proprietary ‘liposomal combination of cytarabine and daunorubicin’ injection, indicated to treat acute myeloid leukemia (AML). The designation follows a positive opinion from the Committee

The alliance intends to develop new drugs for neglected tropical diseases (NTDs). The partnership is expected to generate in excess of $15m investment in drug development for NTDs

Octylseal is a wound closure tissue adhesive that is said to provide a strong, non-invasive alternative to topical sutures. It is also used as a microbial barrier or

This expansion is one of the series of projects that Albemarle is undertaking to meet the growing demand for its metallocene/single site finished catalyst business. A separate production

The approval will allow the company to initiate the commercial manufacturing and packaging of the product for its sales. The company’s marketing partner will distribute the product as

The company adds R&D and commercial scale fluid bed technology, OptiMelt hot melt extrusion, at its German facility and elevates cGMP compliance for handling of OEB class 3

Previstage GCC colorectal cancer staging test provides prognostic information based on the tumour burden measured at the molecular level in the lymph nodes, a key prognostic factor to

The OnkoMatch test is designed for solid tumor cancers such as lung, breast, colon, pancreas, thyroid and skin. The test will analyze 14 oncogenes, genes that drive cancer,